Science
Phase 3 trials in relapsing multiple sclerosis demonstrate efficacy and safety Among the best-in-class for liver safety, setting it apart from competitors

Novartis' relapsing multiple sclerosis (RMS) treatment Rhapsido significantly reduced relapse rates in a phase 3 trial, with no signs of liver toxicity.
According to Fierce Pharma on the 26th (local time), Novartis released phase 3 trial results for Rhapsido in patients with RMS. The data were presented last week at MSToronto and published simultaneously in the medical journal The Lancet.
Based on these results, Novartis plans to seek approval for the RMS indication from regulatory authorities worldwide.
The trials, Remodel-1 and Remodel-2, enrolled more than 2,000 patients in total. Participants took either Rhapsido 100mg twice daily or Sanofi's existing treatment Aubagio 14mg once daily.
Both trials met their primary endpoints. Rhapsido reduced the annualized relapse rate by 35.2% and 31.2%, respectively, compared with Aubagio. Novartis described this as a rate equivalent to about one relapse every 13 years per patient.
Jefferies analysts, however, described the results as "at the low end of expectations." William Blair analysts said the results were numerically inferior to Roche's competing candidate fenebrutinib, but added that cross-trial comparisons should be approached with caution.
In the phase 3 FENhance-1 and -2 trials, Roche's fenebrutinib reduced the annualized relapse rate by 51.1% and 58.5%, respectively, compared with Aubagio.
Rhapsido also showed benefits beyond reducing relapses. It reduced T2 lesion activity detected on brain MRI by 65% and 70% compared with Aubagio, and reduced Gd+T1 lesions by 66% in both trials.
The drug also showed an effect on slowing disease progression. Among patients treated with Rhapsido, 92% experienced no disease progression over 2 years. Six-month confirmed disability progression was reduced by about 30%, but Novartis said this was "nominally significant," indicating that statistical significance was not achieved.
With some efficacy results falling short of expectations, the safety data emerged as a point of differentiation. No liver safety signals or Hy's Law cases were identified among the 2,000 patients in the two trials.
This contrasts with drugs in the same class, which have been hampered by liver toxicity concerns for years. Late last year, the U.S. Food and Drug Administration (FDA) did not approve Sanofi's tolebrutinib as a treatment for nonrelapsing secondary progressive multiple sclerosis. This was because the phase 3 trial identified a risk of drug-induced liver injury, including six Hy's Law cases.
Roche's fenebrutinib also faced a partial clinical hold from the FDA in 2023 after two cases of elevated liver enzyme levels. Aubagio's label also carries a liver toxicity warning.
Dr. Heinz Wiendl, chair of the Department of Neurology and Neurophysiology at the University Medical Center Freiburg in Germany, said the combination of efficacy and safety profiles "has the potential to provide a meaningful and differentiated treatment option for patients with RMS."
Rhapsido first received FDA approval in 2025 as a treatment for chronic spontaneous urticaria. Earlier this month, it received a second approval as a treatment for symptomatic dermographism (SD).
Jefferies analysts projected that Rhapsido could reach peak sales of $3.5 billion if approved for MS. Rhapsido is also being studied in food allergy and hidradenitis suppurativa.

Biobook Team
biobookmedia@biobook.co.kr
Novartis’ Cosentyx approved for 11th indication, becoming first treatment for polymyalgia rheumatica

Oral IL-23-targeting psoriasis drug icotrokinra approved in Brazil; one tablet daily

Aribio’s Oral Alzheimer’s Drug Meets Trial Goal in Monotherapy Group, Slowing Progression by 31%

SELLAS Leukemia Vaccine Extends Survival by 9 Months, Meets Phase 3 Endpoint

Korean Drugmakers Race to Develop Obesity Treatments That Preserve Muscle During Weight Loss

Growth pathway identified in ‘difficult-to-treat’ triple-negative breast cancer, raising potential to repurpose existing drugs